Pancreatic cancer is the third most common cause of cancer death in Australia. Most cases are diagnosed at an advanced stage, when treatment options are limited. Earlier detection offers the best opportunity to improve outcomes. Population screening is not feasible due to the low incidence of the disease. Surveillance of individuals with increased genetic or familial risk therefore represents an important strategy to support earlier diagnosis.
This session introduces the Australian Pancreatic high-RIsk ScrEening (APRISE) Program, a national prospective study that evaluates pancreatic cancer surveillance in individuals at increased risk due to hereditary or familial factors. Participants undergo baseline assessment followed by annual MRI and or endoscopic ultrasound, with multidisciplinary review of any abnormal findings. The study is currently recruiting across 30 hospitals in Australia.
The presentation will outline the rationale for pancreatic cancer surveillance, summarise international evidence, and describe the APRISE study design, eligibility criteria, and surveillance pathway. Early observations from the program will be discussed, together with practical guidance on identifying high-risk individuals and referring patients for assessment.
Attendees will gain a clear overview of pancreatic cancer surveillance, the purpose of APRISE, and how clinicians can refer eligible patients to the program.
Prof Andrew Metz is a gastroenterologist and interventional endoscopist. At the Jreissati Pancreatic Centre, he leads research, clinical care, and patient experience for people with pancreatic cancer. He is also the coordinating Principal Investigator of the Australian Pancreatic high-RIsk ScrEening (APRISE) Program, a national surveillance study for individuals at increased risk of pancreatic cancer. Andrew’s main research interests include the genetics of bowel and pancreatic disease, and the development of novel endoscopic treatments.
